CTNM · Contineum Therapeutics Inc
United States · RS rating 7 · As of 2026-10-14
| Price | 8.14 USD |
|---|---|
| 1-day change | -3.3% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 3 / 7 / 21 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 42 / 17 / 24 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -8.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +53.7% |
| Market cap (USD) | $463.7M |